CONGRESS ABSTRACT

PVOD is a rare form of pulmonary arterial hypertension (PAH) characterized by remodeling of pulmonary venules with intimal fibrosis leading to lumen obliteration, progressive increase in vascular resistance, right heart failure and death. It is essential to distinguish PVOD from other causes of PAH due to its more aggressive…

Introduction. Pulmonary arterial hypertension (PAH) is a rare, chronic, and progressive condition associated with high morbidity and poor prognosis despite advances in pharmacological therapies. Patiens are often required to manage complex multidrug regimens, including not only oral medications but also continuous intravenous or subcutaneous infusion and inhaled therapies, which…

Background Systemic sclerosis–associated pulmonary arterial hypertension (SSc-PAH) is a severe complication affecting 15–18% of SSc patients, with a three-year survival rate below 50%. Early diagnosis is crucial to initiate targeted therapy. Although risk stratification tools such as the ESC/ERS 3-strata model and REVEAL 2.0 score are widely used, they…

Introduction Air pollution is a complex mixture of gases and other molecules that permeate the atmosphere, making exposure largely unavoidable in most indoor and outdoor environments. External, or environmental, pollution can be produced by dumping from numerous sources, including motor vehicles, industrial processes, agricultural dust, fires, etc. All sources…

Autoimmunity plays a central role in the pathogenesis of idiopathic inflammatory myopathy (IIM), with autoantibodies identified in over 50% of patients. These target both nuclear and cytoplasmic cellular components and are classified as myositis–specific (MSAs) or myositis–associated autoantibodies (MAAs), often present in other connective tissue diseases (CTDs). While pulmonary…

A 78 yo male presented to our Cardiology Department complaining of an increasing and severe dyspnoea. His anamnesis was relevant for a previous right myocardial infarction treated with percutaneous coronary angioplasty (PTCA) and a deep vein thrombosis treated with apixaban for 6 months with a recurrence after 4 years…

Background Pulmonary hypertension (PH) in systemic sclerosis (SSc) is a complex and heterogeneous condition, often classified as Group 1 pulmonary arterial hypertension (PAH). However, overlapping mechanisms—including left heart dysfunction (Group 2), interstitial lung disease (Group 3), and chronic thromboembolic disease (Group 4)—are frequent in patients with longstanding, multisystemic SSc….